Grifols, ES0171996087

Wall Street Zen downgrades Grifols stock to Hold at USD 10.00 target

Published on 10/15/2026 at 15:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MyPortfolio lists results for November 10, 2026 with EUR 2.00 billion expected revenue. Grifols stock costs EUR 10.07 on October 15, 2026.

Analyst view and calendar

Wall Street Zen downgraded Grifols from Buy to Hold on October 10, 2026, while the consensus target was USD 10.00.
MyPortfolio listed Grifols for November 10, 2026, with EUR 2.00 billion in expected revenue.
Grifols stock costs EUR 10.07 at Lang & Schwarz on October 15, 2026 at 3:15 p.m. CEST.
Grifols reported EUR 3.6 billion in first-half 2026 revenue and EUR 227.0 million in net profit.

Isometrische 3D-Grafik der Plasma-Wertschöpfungskette von Spende bis Medikament — Isometrische 3D-Illustration zeigt die Wertschöpfungskette von der Plasmaspende bis zum Medikament bei Grifols S.A. ES0171996087, Illustration mit AI erstellt.

Wall Street Zen downgraded Grifols from Buy to Hold on October 10, 2026, while the consensus target reported by MarketBeat was USD 10.00. Against the Nasdaq price of USD 7.24 on October 14, 2026 at 4:00 p.m. ET, that target was 38.12 percent higher.

Results date carries a figure

MyPortfolio listed Grifols for November 10, 2026, with expected revenue of EUR 2.00 billion and expected earnings per share of EUR 0.28. The calendar labels the timing as unconfirmed, so the date is a scheduling marker rather than a company-confirmed release time.

First-half results set the base

Grifols reported revenue of EUR 3.6 billion for the first half of 2026, up 2.6 percent from the prior-year period, while net profit rose 28.7 percent to EUR 227.0 million. Those figures come from the company investor page, which also lists first-quarter 2026 revenue of EUR 1.7 billion and net profit of EUR 73.0 million.Grifols The next report will test whether revenue growth continued into the third quarter.

Price sits inside the yearly range

At Lang & Schwarz, Grifols stock was trading at EUR 10.07 on October 15, 2026 at 3:15 p.m. CEST. The bid was EUR 10.06 and the ask was EUR 10.07 at the same time. The Nasdaq quote was USD 7.24 on October 14, 2026 at 4:00 p.m. ET, while the 52-week Nasdaq range stood at USD 6.96 to USD 9.90 on October 10, 2026.

Valuation and dates

The Nasdaq market capitalization was USD 6.1 billion on October 14, 2026, and the trailing P/E ratio was 15.02. The company profile identifies Grifols as a healthcare group focused on plasma-derived medicines, diagnostics, hospital products and biological supplies. The November 10 reporting date gives the market a defined next checkpoint, while the consensus revenue estimate provides a numerical test for the growth trend.

Comparison with peers

Grifols: EUR 10.07 at Lang & Schwarz on October 15, 2026, Nasdaq market capitalization USD 6.1 billion.
Grifols stock: Nasdaq, USD 7.24 on October 14, 2026, trailing P/E 15.02, market capitalization USD 6.1 billion.
Biogen: Nasdaq, USD 232.83 on October 14, 2026, trailing P/E 41.21, market capitalization USD 34.4 billion.

What the next report will test

The next reporting date matters because the first half combined modest revenue growth with a faster increase in net profit. For investors, the key comparison is whether the expected EUR 2.00 billion in third-quarter revenue supports that pattern.

Grifols was trading at EUR 10.07 at Lang & Schwarz on October 15, 2026 at 3:15 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Grifols stock.